Clinical Trial

IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 9, 2025 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.
Summary
This study was designed to reflect the safety pharmacokinetics and preliminary efficacy of MG-K10 Humanized Monoclonal Antibody Injection in adolescent patients 12-18 weeks of age with moderate to severe atopic dermatitis, administered every 2 or 4 weeks for 8 weeks
Trial Details
NCT Number NCT06765005
Lead Sponsor Shanghai Mabgeek Biotech.Co.Ltd
Conditions Atopic Dermatitis
Enrollment 24 participants
Start Date 2024-07-19
Primary Completion 2025-05 (estimated)
Study Completion 2025-07 (estimated)
Updated on ClinicalTrials.gov 2025-01-09